Devyser Diagnostics Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Devyser Diagnostics wird ein jährliches Gewinn- und Umsatzwachstum von 71.3% bzw. 18.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 71.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 10.6% betragen.
Wichtige Informationen
71.3%
Wachstumsrate der Gewinne
71.46%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 33.2% |
| Wachstumsrate der Einnahmen | 18.7% |
| Zukünftige Eigenkapitalrendite | 10.55% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 29 Jul 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Devyser Diagnostics AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a good week for Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders, because the company has just...Earnings Update: Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders are probably feeling a little disappointed, since its shares...Earnings Miss: Devyser Diagnostics AB (publ) Missed EPS And Analysts Are Revising Their Forecasts
It's been a sad week for Devyser Diagnostics AB (publ) ( STO:DVYSR ), who've watched their investment drop 17% to kr108...Devyser Diagnostics AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders of Devyser Diagnostics AB (publ) ( STO:DVYSR ) will be pleased this week, given that the stock price is up...Devyser Diagnostics AB (publ) (STO:DVYSR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
The analysts might have been a bit too bullish on Devyser Diagnostics AB (publ) ( STO:DVYSR ), given that the company...Recent updates
DVYSR: Italian Tender And New Chimerism Assay Will Support Future Upside
Analysts have reduced their price target for Devyser Diagnostics to SEK 97.58 from SEK 120.86, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News for Devyser Diagnostics Devyser Diagnostics launched the One Lambda Devyser Chimerism Plus assay for chimerism analysis after allogeneic hematopoietic stem cell transplantation, focused on reducing testing errors and improving laboratory efficiency.DVYSR: Italian Tender Wins Will Support Long-Term Genetic Diagnostics Momentum
Analysts have trimmed their price target for Devyser Diagnostics to SEK120.86 from SEK156.12, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E that point to a more conservative valuation framework. What's in the News Devyser Diagnostics launched One Lambda Devyser Chimerism Plus, a next generation solution for chimerism analysis following allogeneic hematopoietic stem cell transplantation.Some Devyser Diagnostics AB (publ) (STO:DVYSR) Analysts Just Made A Major Cut To Next Year's Estimates
The latest analyst coverage could presage a bad day for Devyser Diagnostics AB (publ) ( STO:DVYSR ), with the analysts...
R&D And Partner Risks Will Pressure Margins Before Long-Term Genetics Demand Emerges
Catalysts About Devyser Diagnostics Devyser Diagnostics develops and sells genetic testing kits and services for hereditary disease and transplantation applications. What are the underlying business or industry changes driving this perspective?Devyser Diagnostics' (STO:DVYSR) Earnings Are Of Questionable Quality
Devyser Diagnostics AB (publ) ( STO:DVYSR ) just reported some strong earnings, and the market reacted accordingly with...Devyser Diagnostics AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a good week for Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders, because the company has just...We Think Devyser Diagnostics (STO:DVYSR) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Earnings Update: Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders are probably feeling a little disappointed, since its shares...Earnings Miss: Devyser Diagnostics AB (publ) Missed EPS And Analysts Are Revising Their Forecasts
It's been a sad week for Devyser Diagnostics AB (publ) ( STO:DVYSR ), who've watched their investment drop 17% to kr108...Are Investors Undervaluing Devyser Diagnostics AB (publ) (STO:DVYSR) By 21%?
Key Insights The projected fair value for Devyser Diagnostics is kr156 based on 2 Stage Free Cash Flow to Equity...Devyser Diagnostics AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders of Devyser Diagnostics AB (publ) ( STO:DVYSR ) will be pleased this week, given that the stock price is up...Revenues Tell The Story For Devyser Diagnostics AB (publ) (STO:DVYSR) As Its Stock Soars 31%
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shares have continued their recent momentum with a 31% gain in the last...Optimistic Investors Push Devyser Diagnostics AB (publ) (STO:DVYSR) Shares Up 27% But Growth Is Lacking
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders are no doubt pleased to see that the share price has bounced...Devyser Diagnostics AB (publ) (STO:DVYSR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
The analysts might have been a bit too bullish on Devyser Diagnostics AB (publ) ( STO:DVYSR ), given that the company...Companies Like Devyser Diagnostics (STO:DVYSR) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Devyser Diagnostics AB (publ) (STO:DVYSR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Last week saw the newest full-year earnings release from Devyser Diagnostics AB (publ) ( STO:DVYSR ), an important...Analysts Just Made A Substantial Upgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) Forecasts
Shareholders in Devyser Diagnostics AB (publ) ( STO:DVYSR ) may be thrilled to learn that the analysts have just...Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 27% But Many Are Still Ignoring The Company
The Devyser Diagnostics AB (publ) ( STO:DVYSR ) share price has done very well over the last month, posting an...Devyser Diagnostics AB (publ) (STO:DVYSR) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a pretty great week for Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders, with its shares surging 16...Devyser Diagnostics (STO:DVYSR) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Devyser Diagnostics AB (publ) (STO:DVYSR) Stock Rockets 28% But Many Are Still Ignoring The Company
Devyser Diagnostics AB (publ) ( STO:DVYSR ) shares have had a really impressive month, gaining 28% after a shaky period...These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts
Today is shaping up negative for Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders, with the analysts delivering...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2026 | 258 | 15 | -37 | 26 | N/A |
| 12/31/2025 | 251 | -8 | -62 | 8 | N/A |
| 9/30/2025 | 243 | -25 | -86 | -9 | N/A |
| 3/31/2025 | 221 | -70 | -109 | -40 | N/A |
| 12/31/2024 | 217 | -61 | -128 | -51 | N/A |
| 9/30/2024 | 198 | -71 | -123 | -58 | N/A |
| 6/30/2024 | 196 | -54 | -112 | -61 | N/A |
| 3/31/2024 | 181 | -46 | -120 | -67 | N/A |
| 12/31/2023 | 169 | -54 | -102 | -70 | N/A |
| 9/30/2023 | 158 | -57 | -100 | -69 | N/A |
| 6/30/2023 | 143 | -60 | -102 | -67 | N/A |
| 3/31/2023 | 136 | -60 | -79 | -52 | N/A |
| 12/31/2022 | 127 | -46 | -66 | -40 | N/A |
| 9/30/2022 | 117 | -40 | -53 | -33 | N/A |
| 6/30/2022 | 110 | -35 | -40 | -24 | N/A |
| 3/31/2022 | 101 | -27 | -43 | -29 | N/A |
| 12/31/2021 | 93 | -21 | -25 | -16 | N/A |
| 12/31/2020 | 66 | -11 | -3 | 1 | N/A |
| 12/31/2019 | 64 | 7 | N/A | 15 | N/A |
| 12/31/2018 | 48 | 1 | N/A | 6 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: DVYSRDas prognostizierte Gewinnwachstum (71.3% pro Jahr) liegt über der Sparquote (2.1%).
Ertrag vs. Markt: DVYSRDie Erträge des Unternehmens (71.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (7.1% pro Jahr).
Hohe Wachstumserträge: DVYSREs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: DVYSRDie Einnahmen des Unternehmens (18.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (-1.5% pro Jahr).
Hohe Wachstumseinnahmen: DVYSRDie Einnahmen des Unternehmens (18.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: DVYSRDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (10.6%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/07 21:56 |
| Aktienkurs zum Tagesende | 2026/08/07 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Devyser Diagnostics AB (publ) wird von 4 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Erik Hultgård | DNB Carnegie |
| Ludvig Lundgren | Nordea Markets |